An object of the invention is to provide a method for producing a mesenchymal stem cell in which differentiation into an adipocyte is suppressed with a simple step, a mesenchymal stem cell, a method for producing a differentiation-induced cell using the method for producing a mesenchymal stem cell described above, a differentiation-induced cell, and an inhibitor of differentiation into an adipocyte. According to the invention, there is provided a method for producing a mesenchymal stem cell, including: a step of culturing a mesenchymal stem cell in a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen has been dissolved, wherein differentiation into an adipocyte is suppressed.

The embodiments according to the present disclosure provide a protective solution, a kit, and a method for isolating mitochondria. The kit includes an extraction tube, a protective solution, and a suction needle. The extraction tube is used to contain cells. The protective solution is used to mix with the cells in the extraction tube to form a mixture solution, and the osmolarity of the protective solution is greater than 0 and less than or equal to 220 mOsm/L. The suction needle is used to suck the mixed solution back and forth to facilitate the release of mitochondria from cells. This method and the protective solution may isolate mitochondria from cells with high efficiency in a simple and convenient way, and the isolated mitochondria have excellent good function.

A spheroid formation promoter, including: inorganic particles having adsorbability as an active ingredient; and a method of promoting spheroid formation, including the step of: mixing a dispersion liquid of the spheroid formation promoter and a cell suspension to obtain a mixture in which the inorganic particles having adsorbability contained in the spheroid formation promoter are dispersed, and culturing a cell contained in the obtained mixture to promote spheroid formation.

The present invention chiefly aims to provide a new differentiation inducing agent (peptide) that can solve the previous problems in inducing differentiation of pluripotent stem cells such as ES/iPS cells into somatic cells (e.g., cardiomyocytes).

The present invention can include, for example, a synthetic peptide having, in the molecular structure thereof, an amino acid sequence represented by the following (SEQ ID NO: 1), or an amino acid sequence formed by substitution, deletion and/or addition of one or several amino acid residues in the amino acid sequence. It can also include, for example, a composition for inducing differentiation of pluripotent stem cells into somatic cells, comprising said synthetic peptide.

TABLE-US-00001 (SEQ ID No. 1) C A X X L X X L X X X L X X L X G X X X X X X X X X X X X X X L X X X L X X L X X A C                                                                  • • • 

Provided are a chimeric antigen receptor (CAR) or CAR construct containing antibodies against BCMA and CD19, a nucleic acid molecule encoding the CAR or CAR construct, a modified immune cell, and a method for preparing the immune cell. The CAR or CAR construct and the modified immune cell are used for the prevention and/or treatment of B cell related conditions (e.g., B cell and plasma cell related malignant tumors or autoimmune diseases (such as systemic lupus erythematosus)), and can effectively avoid target escape and prevent the recurrence of multiple myeloma.

A method is provided for producing oligodendrocyte-like cells, including (A) increasing abundances of oligodendrocyte transcription factor 2 (OLIG2) mutant and SRY-box transcription factor 10 (SOX10) in human pluripotent stein cells and (B) culturing the human pluripotent stem cells in which the abundances of the OLIG2 mutant and the SOX10 are increased and consequently differentiating the human pluripotent stem cells into oligodendrocyte-like cells, in which the OLIG2 mutant lacks a serine residue of wild-type OLIG2 at position 147, or the serine residue of the wild-type OLIG2 at position 147 is substituted with an amino acid other than serine.

A method is provided for producing astrocyte-like cells, including (A) upregulating transcription factors including SRY-box transcription factor 9 (SOX9), nuclear factor IA (NFIA), and nuclear factor IB (NFIB) in human pluripotent stein cells and (B) culturing the human pluripotent stem cells, in which the transcription factors are upregulated, and consequently differentiating the human pluripotent stern cells into astrocyte-like cells.

Disclosed is a method for producing an antibody, comprising culturing in a presence of a polyanionic compound an animal cell into which a gene encoding an antibody has been introduced whereby the animal cell produces the antibody, wherein the polyanionic compound is at least one selected from the group consisting of an anionic polysaccharide and an anionic polyamino acid, and the antibody is an antibody in which at least 3 amino acid residues of framework region 3 (FR3) are substituted each independently with an arginine residue or a lysine residue.

The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.

The present invention relates to a composition including a stem cell-derived exosome, and a method for producing same. A composition according to the present invention has excellent effects in terms of anti-inflammatory effects, fibrosis inhibition, vascular endothelial cell proliferation, blood vessel formation, survival rate improvement, and protective regeneration of cardiomyocytes, and thus can be used as an agent for preventing or treating heart disease, inflammatory disease, immune disease, fibrotic disease, or vascular disease.